Egrag Crypto to XRP Army: I Sold 30% of My Bag At Break-even. Here’s why
He said he had sold 30% of his crypto holdings. He described it as “purely strategic positioning,” and it came before the vote.
The Analyst’s Strategy
EGRAG CRYPTO was transparent about his reasoning. He sold at roughly break-even, meaning he took no profit on the position. His stated logic covers both potential market outcomes.
If the market drops, he plans to use that liquidity to buy the dip and accumulate more tokens. However, if the market reacts positively, he stated that he is comfortable holding his remaining 70% bag through the move. He summarized his approach as “Not fear. Not FOMO. Just risk management.”
The Context
The CLARITY Act cloture vote was one of the most consequential moments in recent crypto legislative history. For XRP holders, the stakes were and still are significant. The bill provides statutory clarity on digital asset jurisdiction, going beyond the legal precedent established through Ripple’s legal battle.
He sold a portion not because he expected failure, but because he chose not to hold a full bag through an uncertain event.
Positioned Either Way
EGRAG CRYPTO’s disclosure reflects calculated preparation rather than conviction in one direction. Many market participants were optimistic about a major rally following the vote, but EGRAG CRYPTO prepared for all outcomes. The outcome will now determine which part of his plan activates.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After Eli Lilly's nearly 300% surge in four years, Wall Street remains bullish: The "hidden pipeline" beyond GLP-1 is underestimated
Eli Lilly’s share price has surged nearly 300% since the approval of its first GLP-1 drug, with its market capitalization surpassing 1 trillion USD, yet Wall Street remains optimistic about its continued growth. Berenberg has upgraded Eli Lilly’s rating to “Buy," believing that Mounjaro and Zepbound will continue to see strong volume, and that the oral GLP-1 drug could further drive demand. Additionally, Eli Lilly continues to expand into areas such as cancer and sleep disorders, and the potential of its non-obesity-related pipelines remains underestimated by the market.
BUZZ — U.S. Stock Market News: CoreWeave, StubHub, Ultragenyx
Goldman Sachs: The industrial sector is "even more expensive" than tech stocks; global sector pricing logic is changing
The 12-month forward price-to-earnings ratio of the industrial sector has now surpassed that of the technology sector, indicating that the relative valuations among various sectors in global stock markets are undergoing a shift.
BrasilAgro updates corporate financial calendar for 2026-27
